| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 12/27/2001 | WO2001098297A2 A thiazine oxazolidinone |
| 12/27/2001 | WO2001098206A1 Delivery vehicle composition and methods for delivering antigens and other drugs |
| 12/27/2001 | WO2001098067A1 Nucleated molded article, method of producing the same, and device for producing the same |
| 12/27/2001 | WO2001097887A1 Delivery of bronchially provocative agents |
| 12/27/2001 | WO2001097872A1 Bioadhesive compositions and methods of preparation and use |
| 12/27/2001 | WO2001097865A2 Multiple phase cross-linked compositions and uses thereof |
| 12/27/2001 | WO2001097859A1 Liposomal encapsulation of chelated actinium-225 and uses thereof |
| 12/27/2001 | WO2001097857A1 Preparations for oligonucleotide transfer |
| 12/27/2001 | WO2001097851A2 Compositions and methods to improve the oral absorption of antimicrobial agents |
| 12/27/2001 | WO2001097837A1 Solubilised protein vaccines |
| 12/27/2001 | WO2001097834A1 Matrix protein compositions for dentin regeneration |
| 12/27/2001 | WO2001097832A1 Pharmaceutical preparations containing cyclosporines and neutral oils |
| 12/27/2001 | WO2001097821A1 Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor. |
| 12/27/2001 | WO2001097813A2 Highly concentrated stable meloxicam solutions |
| 12/27/2001 | WO2001097811A1 Method for the treatment of overactive bladder |
| 12/27/2001 | WO2001097807A1 New use of angiotensin ii antagonists |
| 12/27/2001 | WO2001097805A2 Solid valsartan pharmaceutical compositions |
| 12/27/2001 | WO2001097803A1 Pharmaceutical preparations comprising racecadotril (acetorphan) |
| 12/27/2001 | WO2001097801A2 Dry powder formulation comprising racecadotril |
| 12/27/2001 | WO2001097796A1 Clear aqueous anaesthetic composition |
| 12/27/2001 | WO2001097795A2 Systems and methods for treating a mucosal surface |
| 12/27/2001 | WO2001097788A2 Method of administering bisphosphonates |
| 12/27/2001 | WO2001097783A1 Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| 12/27/2001 | WO2001097782A1 Stable gabapentin having ph within a controlled range |
| 12/27/2001 | WO2001097781A1 Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake |
| 12/27/2001 | WO2001097780A2 Pharmaceutical compositions comprising an opioid analgesic |
| 12/27/2001 | WO2001097779A2 Improved injectable dispersions of propofol |
| 12/27/2001 | WO2001097778A2 Amphotericin b structured emulsion |
| 12/27/2001 | WO2001097777A1 Topical preparation of alprostadil for the treatment of erectile dysfunction |
| 12/27/2001 | WO2001097776A1 Polymer-containing drug composition |
| 12/27/2001 | WO2001097775A2 Controlled release anti-inflammatory formulation |
| 12/27/2001 | WO2001097774A2 Novel pharmaceutical composition for the topical application of water-insoluble and/or hardly water-soluble active agents |
| 12/27/2001 | WO2001097753A2 Novel methods using pyridine derivatives |
| 12/27/2001 | WO2001097749A2 The use of synthetic, non-hormonal 21-aminosteroids and thereof |
| 12/27/2001 | WO2001097637A2 Production of oil encapsulated minerals and vitamins in a glassy matrix |
| 12/27/2001 | WO2001097635A2 Microcapsules containing arginine and the different uses thereof |
| 12/27/2001 | WO2001097627A1 Throat care agents |
| 12/27/2001 | WO2001097612A1 Stable gabapentin containing more than 2o ppm of chlorine ion |
| 12/27/2001 | WO2001097611A1 Positively charged poly[alpha-(omega-aminoalkyl)glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake |
| 12/27/2001 | WO2001062086A8 Nutritional intervention composition for enhancing and extending satiety |
| 12/27/2001 | WO2001060349B1 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof. |
| 12/27/2001 | WO2001052634A3 Delivering substances to invertebrate organisms |
| 12/27/2001 | WO2001051031A3 Enteric coated pharmaceutical formulation |
| 12/27/2001 | WO2001051024A3 Implantation kit comprising a support phase and a solvent |
| 12/27/2001 | WO2001045672A3 Mixed structures resulting from the incorporation of a biological macromolecule in a liquid crystal phase of amphiphiles |
| 12/27/2001 | WO2001041771A3 Transdermal system containing acetylsalicylic acid for treatment of migraine |
| 12/27/2001 | WO2001037813A3 Multilayer preparation for a controlled, pulsed release of active substances |
| 12/27/2001 | WO2001037783A3 Article comprising a diffuser with flow control features |
| 12/27/2001 | WO2001037782A3 Method and composition for the treatment of scars |
| 12/27/2001 | WO2001035926A3 An improved pharmaceutical composition for treating male erectile dysfunction |
| 12/27/2001 | WO2001030336A3 Pharmaceutical formulations comprising resveratrol and use thereof |
| 12/27/2001 | WO2001022917A3 Effervescent compositions comprising nimesulide |
| 12/27/2001 | WO2001021159A3 Pharmaceutical composition of nateglinide and another antidiabetcagent |
| 12/27/2001 | US20010056301 Hydrogel biomedical articles |
| 12/27/2001 | US20010056267 Pack for the nose |
| 12/27/2001 | US20010056255 Effect of electric field and ultrasound for transdermal drug delivery |
| 12/27/2001 | US20010056183 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 12/27/2001 | US20010056127 Contains molecular iodine in a concentration above at least 15 ppm and one of triiodide or complexed iodoine may be present; lower concentrations of iodine disinfect without staining skin |
| 12/27/2001 | US20010056113 Methods for the inhibition of angiogenesis with 6-amino EM-12 |
| 12/27/2001 | US20010056098 Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid |
| 12/27/2001 | US20010056093 Olopatadine and emedastine and an ophthalmically acceptable polymeric quaternary ammonium compound as a preservative |
| 12/27/2001 | US20010056074 Novel lipophilic compounds having affinity with nucleic acids and therapeutical uses thereof |
| 12/27/2001 | US20010056069 Use of collagen for the treatment of degenerative articular processes |
| 12/27/2001 | US20010056063 Method of treating or preventing type 1 diabetes by oral administration of insulin |
| 12/27/2001 | US20010056062 As osmotic agents synthetic polypeptides of two to fifteen amino acids long; slow transport across the peritoneum, for prolonged osmotic gradient between dialysate and blood |
| 12/27/2001 | US20010055807 Immunoisolation of a cell; least one cell is encapsulated with a coating having a polyelectrolyte charge opposite to the charge of the cell/poly-beta-N-acetylglucosamine species |
| 12/27/2001 | US20010055622 Antimicrobial bioabsorbable materials |
| 12/27/2001 | US20010055620 Compaction; particle coatings |
| 12/27/2001 | US20010055619 Mixture of polymethacrylate and carboxymethyl cellulose |
| 12/27/2001 | US20010055617 Method and preparations for stabilizing biological materials by drying methods without freezing |
| 12/27/2001 | US20010055616 Multilayer; active material core, enteric coating |
| 12/27/2001 | US20010055614 Osmosis dosage form |
| 12/27/2001 | US20010055613 Oral pulsed dose drug delivery system |
| 12/27/2001 | US20010055612 Extended release formulation |
| 12/27/2001 | US20010055611 Freeze drying |
| 12/27/2001 | US20010055610 Medicament administration system |
| 12/27/2001 | US20010055608 Applying moisture containing hydrophilic gel patch |
| 12/27/2001 | US20010055607 Intranosally administering of anesthetics |
| 12/27/2001 | US20010055602 Topical applying |
| 12/27/2001 | US20010055598 Mixture with solvent and hydrophobic carrier |
| 12/27/2001 | US20010055583 Methods of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby |
| 12/27/2001 | US20010055582 Erythropoietin solution preparation |
| 12/27/2001 | US20010055571 Controlled unit dose to induce sedative-anxiolytic physiological response in the mammal, comprising lorazepam, nonaqueous, organic liquid solvent carrier and a preservative, in a manually actuated spray device |
| 12/27/2001 | US20010055570 Cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDEs); using specified pyrazolopyrimidinone or aminoquinazoline derivatives |
| 12/27/2001 | US20010055569 Nasal drug delivery composition |
| 12/27/2001 | US20010055568 Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| 12/27/2001 | CA2713965A1 Glycopeptide phosphonate derivatives |
| 12/27/2001 | CA2414064A1 Clear aqueous anaesthetic composition |
| 12/27/2001 | CA2413860A1 Regulation of cellproliferation and differentiation using topically applied peptides |
| 12/27/2001 | CA2413253A1 Matrix protein compositions for dentin regeneration |
| 12/27/2001 | CA2412905A1 Improved injectable dispersions of propofol |
| 12/27/2001 | CA2411826A1 Liposomal encapsulation of chelated actinium-225 and uses thereof |
| 12/27/2001 | CA2411553A1 New use of angiotensin ii antagonists |
| 12/27/2001 | CA2410358A1 A thiazine oxazolidinone |
| 12/27/2001 | CA2410208A1 Systems and methods for treating a mucosal surface |
| 12/27/2001 | CA2312505A1 Resveratrol compositions for topical use in the treatment of oral diseases and infections |
| 12/26/2001 | CN2467106Y Gas-electric conversion controlling antiexplosive boiling pelleter |
| 12/26/2001 | CN1328573A Cross-linked hyaluronic acids and medical uses thereof |
| 12/26/2001 | CN1328489A Milling process for production of finely milled medicinal substances |
| 12/26/2001 | CN1328475A Coating useful as dispenser of active ingredient no dressings and bandages |